Immunogenicity in a Prime-boost Regimen of a Modified Vaccinia Virus Ankara (MVA) Vectored Experimental HIV-1 Clade C/B’ Vaccine
- VernacularTitle:HIV-1 C/B’亚型多价重组MVA病毒疫苗免疫原性的研究
- Author:
Yan GAO
;
Ming SUN
;
Guo-Run JIANG
;
Yin-Chuan ZHANG
;
Xi WANG
;
Bing-Xiang LI
;
Xiao-Qin HUANG
;
Dan CHEN
;
Dong-Xia ZHOU
;
Jiayou CHU
;
- Publication Type:Journal Article
- Keywords:
HIV-1 clade C/B’ MVA Vaccine Immunogenicity
- From:
China Biotechnology
2006;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the immunogenicity of HIV-1 clade C/B’ vaccine based on modified vaccinia virus Ankara (MVA) vector in mice. Methods: Mice were inoculated with 3-dose HIV vaccine by intramuscular injection. Blood sample were collected every second week, and then the antibodies against HIV were detected. At week 6, mice were killed and cellular immune responses were examined by ELISPOT. Result: The number of spot forming cells in the 107 pfu/ml -dose group was more than those of 105 pfu/ml -dose and 106 pfu/ml -dose groups significantly. HIV specific antibodies emerged at week 2 and elevated rapidly at week 4 and week 6. The level of specific IgG in the 107 pfu/ml -dose group was more than those of 105 pfu/ml -dose and 106 pfu/ml -dose groups significantly. Conclusion: The ADMVA induces both humoral immunoresponse and cellular immune responses.
